Besides, it was revealed that these immunoglobulins may involve in cell survival and promote tumor growth and migration [34, 35]

Besides, it was revealed that these immunoglobulins may involve in cell survival and promote tumor growth and migration [34, 35]. cell sarcoma (FDCS), interdigitating dendritic cell sarcoma (IDCS) and histiocytic sarcoma (HS). Among them, twenty-eight cases were sporadic without current or past lymphoma/leukemia. Three cases were discovered with a past history of T-cell lymphoma, 1 case was followed by extraosseous plasmacytoma, and one case was discovered with diffuse large B-cell lymphoma (DLBCL). Our results showed that there was a higher frequency of clonal IG and T-cell receptor gene rearrangements in these cases. Notably, 4 cases of LCH and 2 cases of FDCS showed both B and T cell receptor gene rearrangements concurrently. One case of FDCS synchronous with DLBCL showed identical clonal IGH in both tumor populations and clonal TCR in FDCS alone. No matter if the presence of clonal receptor gene rearrangements was associated with the tumor origin or tumorigenesis, it might serve as a novel tumor marker to get developing target therapy. Keywords: histiocytic sarcoma, Langerhans cell histiocytosis, Langerhans (Rac)-Antineoplaston A10 cell sarcoma, interdigitating dendritic cell sarcoma, follicular dendritic cell sarcoma, Pathology Section == INTRO == Histiocytic and dendritic cell neoplasms are rare among the tumors of hemapoietic and lymphoid tissues, and only account for less than 1% of hematolymphoid tumors presenting in lymph nodes [1]. They can also occur in extranodal sites, such as skin, liver, bone and soft cells [26]. Histiocytic and dendritic cell neoplasms are consisted of a group of tumors including histiocytic sarcoma (HS), Langerhans cell (Rac)-Antineoplaston A10 histiocytosis/Langerhans cell sarcoma (LCH/LCS), interdigitating dendritic cell sarcoma (IDCS) and follicular dendritic cell sarcoma (FDCS). The histogenetic origins of those tumors are from myeloid-derived macrophages, myeloid-derived dendritic cells, and stromal-derived dendritic cells, which separately are the precursors of histiocytes, Langerhans cells and a part of the interdigitating cells, and follicular dendritic cells. The recognition of tumors has changed in the last two decades. In 2001 the World Health Business (WHO) classification of tumors of the hematopoietic and lymphoid tissues defined histiocytic and dendritic cell neoplasms as a tumor without clonal W or To cell receptor gene rearrangements [7]. But in 2008 [1], the WHO ALSO classification explained rare cases of HS, IDCS, and FDCS that have been reported to have antigen receptor gene rearrangements. The reason for this modification was that clonal W or To cell receptor gene rearrangements had been determined in a few cases of HS and LCH, which was reported, previously, simultaneously or consequently to a non-Hodgkin’s lymphoma, such as precursor W or T-lymphoblastic leukemia/lymphoma [811], follicular lymphoma [12] and myeloid leukemia/sarcoma [13, 14]. In addition , in the investigation by Chen [15] et al, 39% cases of sporadic histiocytic/dendritic cell sarcomas without either a past history or a concurrent diagnosis of any type of lymphoma showed clonal IGH (IGK) gene rearrangements. This provided evidence that there was a higher frequency Rabbit Polyclonal to OR13C8 of clonal immunoglobulin receptor gene rearrangements in sporadic histiocytic/dendritic cell sarcoma. In order to get further information about the molecular characteristics of histiocytic and dendritic cell neoplasms and to learn more about the nature of the correlation between such number of tumors and lymphoma/leukemia, we investigated the clonal status of 33 samples that included LCH, LCS, FDCS, IDCS, and HS. Twenty eight of these cases were sporadic without a history or concurrent with lymphoma/leukemia, while three cases were with a past history of T-cell lymphoma, 1 case was followed extraosseous plasmacytoma, and one case was concomitant with diffuse large B-cell lymphoma (DLBCL). == RESULTS == == Clinical features == Almost all patients enrolled in this study ranged in age from 8 to 74 years (median, 42 years). Among 33 patients, 20 were male and 13 were female. The demographic and clinical characteristics of LCH, LCS, FDCS, IDCS and HS were listed in Table1, respectively. The most common primary site of LCH was bone. And in our study almost all 5 cases of HS occurred in lymph node. Because shown in the Table1, tonsil was the most common extranodal site of FDCS. == Table 1 . Clinical Characteristics of all samples. == == Morphological features == Thirteen cases of LCH contained a large number of cells with all the characteristics of grooved, folded or lobulated nuclei. A variable number of eosinophils, neutrophils, histiocytes and small lymphocytes were scattered among tumor cells. Compared to LCH, 2 cases of LCS showed considerable pleomorphism, nuclear atypia, and large mitotic activity. Furthermore, eosinophils were decreased so that in some area they were difficult to be found. In LCH and LCS, tumor cells were typically stained positive for CD1 and S-100 (Figure1A-1D). == Figure 1 . LCH (A-C). == A. A variable number of eosinophils were admixed with tumor cells (H&E100); B. Tumor cells had grooved, folded nuclei with (Rac)-Antineoplaston A10 inconspicuous nucleoli (H&E400); C. Staining was both nuclear and cytoplasmic with S100 (200); Deb. Tumor cells were diffuse strong positive for CD1(200). (Rac)-Antineoplaston A10 FDCS (E-G): E. Tumor cells had indistinct cytoplasmic outlines,.